About: Human coronavirus OC43 3CL protease and the potential of ML188 as a broad-spectrum lead compound: Homology modelling and molecular dynamic studies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Human coronavirus OC43 3CL protease and the potential of ML188 as a broad-spectrum lead compound: Homology modelling and molecular dynamic studies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Human coronavirus OC43 3CL protease and the potential of ML188 as a broad-spectrum lead compound: Homology modelling and molecular dynamic studies
Creator	Berry, Michael Gamieldien, Junaid Fielding, Burtram
Source	Medline; PMC
abstract	BACKGROUND: The coronavirus 3 chymotrypsin-like protease (3CL(pro)) is a validated target in the design of potential anticoronavirus inhibitors. The high degree of homology within the protease’s active site and substrate conservation supports the identification of broad spectrum lead compounds. A previous study identified the compound ML188, also termed 16R, as an inhibitor of the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) 3CL(pro). This study will detail the generation of a homology model of the 3CL(pro) of the human coronavirus OC43 and determine the potential of 16R to form a broad-spectrum lead compound. MODELLER was used to generate a suitable three-dimensional model of the OC43 3CL(pro) and the Prime module of Schrӧdinger predicted the binding conformation and free energy of binding of 16R within the 3CL(pro) active site. Molecular dynamics further confirmed ligand stability and hydrogen bonding networks. RESULTS: A high quality homology model of the OC43 3CL(pro) was successfully generated in an active conformation. Further studies reproduced the binding pose of 16R within the active site of the generated model, where its free energy of binding was shown to equal that of the 3CL(pro) of SARS-CoV, a receptor it is experimentally proven to inhibit. The stability of the ligand was subsequently confirmed by molecular dynamics. CONCLUSION: The lead compound 16R may represent a broad-spectrum inhibitor of the 3CL(pro) of OC43 and potentially other coronaviruses. This study provides an atomistic structure of the 3CL(pro) of OC43 and supports further experimental validation of the inhibitory effects of 16R. These findings further confirm that the 3CL(pro) of coronaviruses can be inhibited by broad spectrum lead compounds.
has issue date	2015-04-28(xsd:dateTime)
bibo:doi	10.1186/s12900-015-0035-3
bibo:pmid	25928480
has license	cc-by
sha1sum (hex)	03fa4232b3fbc44b6029d52c3120f4e82fdc49c0
schema:url	https://doi.org/10.1186/s12900-015-0035-3
resource representing a document's title	Human coronavirus OC43 3CL protease and the potential of ML188 as a broad-spectrum lead compound: Homology modelling and molecular dynamic studies
has PubMed Central identifier	PMC4411765
has PubMed identifier	25928480
schema:publication	BMC Struct Biol
resource representing a document's body	covid:03fa4232b3fbc44b6029d52c3120f4e82fdc49c0#body_text
is schema:about of	named entity 'MOLECULAR DYNAMIC' named entity 'SARS-CoV' named entity 'OC43' named entity 'module' named entity 'validation' named entity 'broad-spectrum' named entity 'lead compound' named entity 'HUMAN CORONAVIRUS OC43' named entity 'THESE' named entity 'GENERATE' named entity 'CONFIRMED' named entity 'POTENTIAL' named entity 'CORONAVIRUSES' named entity 'BROAD SPECTRUM' named entity 'USED' named entity 'INHIBITED' named entity 'CONFORMATION' named entity 'HUMAN CORONAVIRUS OC43' named entity 'FINDINGS' named entity 'TARGET' named entity 'PROTEASE' named entity 'CORONAVIRUS' named entity 'ITS' named entity 'CONCLUSION' named entity 'SPECTRUM' named entity 'COMPOUND' named entity 'HOMOLOGY MODEL' named entity 'LEAD COMPOUND' named entity 'PREVIOUS' named entity 'CHYMOTRYPSIN-LIKE PROTEASE' named entity 'BROAD' named entity 'REPRESENT' named entity 'INHIBITOR' named entity 'EXPERIMENTAL' named entity 'CONFIRM' named entity 'STUDIES' named entity 'RESULTS' named entity 'IDENTIFICATION' named entity 'ACTIVE' named entity 'LIGAND' named entity 'SARS-COV' named entity 'IDENTIFIED' named entity 'EFFECTS' named entity 'GENERATION' named entity 'STUDY' named entity 'EQUAL' named entity 'PROVEN' named entity 'ACTIVE SITE' named entity 'PROTEASE' named entity 'MODELLER' named entity '27S' named entity 'HYDROGEN BONDING' named entity 'PRIME' named entity 'SITE OF' covid:arg/03fa4232b3fbc44b6029d52c3120f4e82fdc49c0 named entity 'POTENTIAL' named entity 'HOMOLOGY MODELLING' named entity 'STUDIES' named entity 'LEAD COMPOUND' named entity 'WHERE' named entity 'VALIDATION' named entity 'PREDICTED' named entity 'INHIBITORS' named entity 'DEGREE' named entity 'OC43' named entity 'HOMOLOGY' named entity 'PRO' named entity 'MODULE' named entity 'CONFIRMED BY' named entity 'TO INHIBIT' named entity 'MODEL OF' named entity 'RECEPTOR' named entity 'NETWORKS' named entity 'THREE-DIMENSIONAL' named entity 'IS A' named entity 'FREE ENERGY' named entity 'STABILITY' named entity 'SUITABLE' named entity 'MODEL'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software